CAPR — Capricor Therapeutics Share Price
Last trade - 00:00- $356.39m
- $118.46m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.45 | ||
| Price to Tang. Book | 1.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.25% | ||
| Return on Equity | -73.7% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.24 | 2.55 | 25.18 | 22.27 | n/a | 49.08 | 38.78 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Directors
- Frank Litvack CHM
- Linda Marban PRE (57)
- Anthony Bergmann CFO (35)
- Karen Krasney EVP (68)
- Karimah Es Sabar DRC
- Earl Collier IND (73)
- George Dunbar IND (74)
- Louis Manzo IND (83)
- David Musket IND (63)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 26th, 2007
- Public Since
- June 4th, 2002
- No. of Shareholders
- 112
- No. of Employees
- 231
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 58,138,989
- Address
- 10865 Road to the Cure, Suite 150, SAN DIEGO, 92121
- Web
- https://capricor.com/
- Phone
- +1 3026587581
- Auditors
- Rose, Snyder & Jacobs
Latest News for CAPR
Upcoming Events for CAPR
Q3 2026 Capricor Therapeutics Inc Earnings Release
Q4 2026 Capricor Therapeutics Inc Earnings Release
Similar to CAPR
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 01:49 UTC, shares in Capricor Therapeutics are trading at $6.13. This share price information is delayed by 15 minutes.
Shares in Capricor Therapeutics last closed at $6.13 and the price had moved by -1.61% over the past 365 days. In terms of relative price strength the Capricor Therapeutics share price has underperformed the S&P500 Index by -13.48% over the past year.
The overall consensus recommendation for Capricor Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCapricor Therapeutics does not currently pay a dividend.
Capricor Therapeutics does not currently pay a dividend.
Capricor Therapeutics does not currently pay a dividend.
To buy shares in Capricor Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.13, shares in Capricor Therapeutics had a market capitalisation of $356.39m.
Here are the trading details for Capricor Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CAPR
Based on an overall assessment of its quality, value and momentum Capricor Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Capricor Therapeutics is $23.67. That is 286.13% above the last closing price of $6.13.
Analysts covering Capricor Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.24 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Capricor Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -83.73%.
As of the last closing price of $6.13, shares in Capricor Therapeutics were trading -71.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Capricor Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Capricor Therapeutics' management team is headed by:
- Frank Litvack - CHM
- Linda Marban - PRE
- Anthony Bergmann - CFO
- Karen Krasney - EVP
- Karimah Es Sabar - DRC
- Earl Collier - IND
- George Dunbar - IND
- Louis Manzo - IND
- David Musket - IND